rs72555359
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000404.4(GLB1):c.1369C>T(p.Arg457*) variant causes a stop gained change. The variant allele was found at a frequency of 0.00000805 in 1,613,910 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000404.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152146Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000160 AC: 4AN: 249532Hom.: 0 AF XY: 0.0000222 AC XY: 3AN XY: 135374
GnomAD4 exome AF: 0.00000821 AC: 12AN: 1461764Hom.: 0 Cov.: 31 AF XY: 0.00000963 AC XY: 7AN XY: 727184
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152146Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74324
ClinVar
Submissions by phenotype
Infantile GM1 gangliosidosis Pathogenic:4
- -
- -
The observed stop gained c.1369C>Tp.Arg457Ter variant in GLB1 gene has been reported previously in homozygous and compound heterozygous states in multiple individuals affected with GM1 gangliosidosis Fu F, et al., 2018; Bidchol AM, et al., 2015; Santamaria R, et al., 2007. The c.1369C>T variant is present with allele frequency of 0.002% in gnomAD Exomes. This variant has been submitted to the ClinVar database as Pathogenic multiple submissions. Computational evidence MutationTaster - Disease causing predicts damaging effect on protein structure and function for this variant.The nucleotide change c.1369C>T in GLB1 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. This sequence change creates a premature translational stop signal p.Arg457Ter in the GLB1 gene. This variant is predicted to cause loss of normal protein function through protein truncation. Loss of function variants in GLB1 gene have been previously reported to be disease causing Brunetti-Pierri N, Scaglia F., 2008. For these reasons, this variant has been classified as Pathogenic. -
- -
not provided Pathogenic:2
GLB1: PM3:Strong, PVS1:Strong, PM2, PP4 -
- -
Mucopolysaccharidosis, MPS-IV-B;C0268271:Infantile GM1 gangliosidosis;C0268272:GM1 gangliosidosis type 2;C0268273:GM1 gangliosidosis type 3 Pathogenic:1
- -
GM1 gangliosidosis Pathogenic:1
Variant summary: GLB1 c.1369C>T (p.Arg457X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 1.6e-05 in 249532 control chromosomes (gnomAD). c.1369C>T has been reported in the literature in individuals affected with GM1 gangliosidosis (e.g. Nishimoto_1991, Santamaria_2007, Matalonga_2015). These data indicate that the variant is likely to be associated with disease. Cells expressing the variant were shown to have indetectable levels of acid beta-galactosidase enzymatic activity (Nishimoto_1991). One Clin Var submitter (evaluation after 2014 ) cited the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
GM1 gangliosidosis;C0086652:Mucopolysaccharidosis, MPS-IV-B Pathogenic:1
This sequence change creates a premature translational stop signal (p.Arg457*) in the GLB1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GLB1 are known to be pathogenic (PMID: 18524657). This variant is present in population databases (rs72555359, gnomAD 0.006%). This premature translational stop signal has been observed in individuals with GM1 gangliosidosis (PMID: 1909089, 25936995, 28976722, 30548430). ClinVar contains an entry for this variant (Variation ID: 924). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
GM1 gangliosidosis type 2 Pathogenic:1
The stop gained c.1369C>T (p.Arg457Ter) variant in GLB1 gene has been reported previously in homozygous and compound heterozygous states in multiple individuals affected with GM1 gangliosidosis (Fu et al., 2018; Bidchol et al., 2015; Santamaria et al., 2007). Experimental studies showed that cells expressing the variant had indetectable levels of acid beta-galactosidase enzymatic activity (Nishimoto, 1991). The c.1369C>T variant is present with allele frequency of 0.002% in gnomAD Exomes. This variant has been submitted to the ClinVar database as Pathogenic (multiple submissions). Computational evidence (MutationTaster - Disease causing) predicts damaging effect on protein structure and function for this variant. The nucleotide change c.1369C>T in GLB1 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. This sequence change creates a premature translational stop signal (p.Arg457Ter) in the GLB1 gene. This variant is predicted to cause loss of normal protein function through protein truncation. Loss of function variants in GLB1 gene have been previously reported to be disease causing (Brunetti-Pierri and Scaglia, 2008). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at